BlinkLab’s smartphone-based Dx1 autism screening technology has been selected for Morocco’s government-funded national early screening program, marking a major milestone in digital health adoption and autism care.
- BlinkLab’s Dx1 chosen for Morocco’s nationwide early autism screening
- Program funded by Moroccan government and Foundation Mohammed V
- Screening starts at 18 months, targeting over 400,000 affected individuals
- BlinkLab retains data ownership and supports clinical rollout without capital costs
- Initiative includes a new Center of Excellence and expert consortium involvement
A Landmark National Initiative
In a pioneering move, the Kingdom of Morocco has launched a government-funded nationwide autism screening program, selecting BlinkLab’s Dx1 smartphone-based technology as its cornerstone. This initiative, endorsed by multiple ministries and under the High Instructions of His Majesty King Mohammed VI, aims to systematically screen children from 18 months of age across the country. With approximately 600,000 births annually and an estimated 400,000 individuals affected by autism, Morocco is positioning itself as a global leader in early autism diagnosis and intervention.
BlinkLab’s Role and Strategic Significance
BlinkLab’s Dx1 platform, which leverages artificial intelligence and machine learning to provide objective, reflex-based neurometric assessments, will be integrated into public primary healthcare centres nationwide. The Moroccan government and the Foundation Mohammed V for Solidarity will fully fund the clinical rollout, infrastructure, and implementation costs, allowing BlinkLab to focus on technology deployment and data management. This large-scale adoption offers BlinkLab a unique real-world validation opportunity ahead of its pending FDA clearance, reinforcing its global regulatory and commercial narrative.
Building Capacity and Expertise
Beyond screening, the program includes the establishment of a Center of Excellence for Autism Research, Education, and Training. BlinkLab’s Managing Director and CEO, Dr Henk-Jan Boele, along with Scientific Advisor Prof Abdeslem El Idrissi, will join a consortium of international experts guiding the initiative. This collaboration underscores the company’s leadership in digital autism diagnostics and supports capacity building within Morocco’s healthcare system.
Implications for Regional Expansion and Healthcare Equity
The Moroccan framework is designed with a regional outlook, potentially serving as a model for other North African and Middle Eastern countries investing in digital health transformation. The use of smartphone technology enables scalable, equitable access to early autism screening in diverse healthcare and community settings, aligning with World Health Organization standards. This approach could help address longstanding challenges such as healthcare bottlenecks and inequities in access to neurodevelopmental care.
Commercial Outlook and Next Steps
While the program does not generate immediate revenue for BlinkLab, it establishes a foundation for future commercial discussions post-FDA approval. The company retains ownership of all data generated and intellectual property improvements arising from the program. As the initiative rolls out starting April 2026, BlinkLab’s progress in Morocco will be closely watched as a bellwether for its broader global ambitions in digital health diagnostics.
Bottom Line?
BlinkLab’s Moroccan partnership sets the stage for transformative growth and global validation in autism screening technology.
Questions in the middle?
- How will BlinkLab’s pending FDA clearance impact commercial terms with Morocco?
- What are the prospects for regional expansion into other North African and Middle Eastern countries?
- How will data ownership and privacy be managed across this large-scale government program?